Peter J. Eggenhuizen

1.0k total citations
31 papers, 548 citations indexed

About

Peter J. Eggenhuizen is a scholar working on Pulmonary and Respiratory Medicine, Immunology and Nephrology. According to data from OpenAlex, Peter J. Eggenhuizen has authored 31 papers receiving a total of 548 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 13 papers in Immunology and 10 papers in Nephrology. Recurrent topics in Peter J. Eggenhuizen's work include Vasculitis and related conditions (16 papers), Renal Diseases and Glomerulopathies (8 papers) and Neutrophil, Myeloperoxidase and Oxidative Mechanisms (5 papers). Peter J. Eggenhuizen is often cited by papers focused on Vasculitis and related conditions (16 papers), Renal Diseases and Glomerulopathies (8 papers) and Neutrophil, Myeloperoxidase and Oxidative Mechanisms (5 papers). Peter J. Eggenhuizen collaborates with scholars based in Australia, China and United States. Peter J. Eggenhuizen's co-authors include Joshua D. Ooi, Boaz H. Ng, Stephen R. Holdsworth, A. Richard Kitching, Janet Chang, Yong Zhong, Kim M. O’Sullivan, Ting Meng, Chanjuan Shen and Rong Tang and has published in prestigious journals such as Nature Communications, PLoS ONE and Development.

In The Last Decade

Peter J. Eggenhuizen

28 papers receiving 535 citations

Peers

Countries citing papers authored by Peter J. Eggenhuizen

Since Specialization

Citations

This map shows the geographic impact of Peter J. Eggenhuizen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J. Eggenhuizen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J. Eggenhuizen more than expected).

Fields of papers citing papers by Peter J. Eggenhuizen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter J. Eggenhuizen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J. Eggenhuizen. The network helps show where Peter J. Eggenhuizen may publish in the future.

Co-authorship network of co-authors of Peter J. Eggenhuizen

This figure shows the co-authorship network connecting the top 25 collaborators of Peter J. Eggenhuizen. A scholar is included among the top collaborators of Peter J. Eggenhuizen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter J. Eggenhuizen. Peter J. Eggenhuizen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Regulatory T cell therapies: from patient data to biological insights 2025 ·Frontiers in Immunology ·(unknown), Peter J. Eggenhuizen, Rosa Bacchetta, Zinaida Good	0
2	Engineered antigen-specific T regulatory cells suppress autoreactivity to the anti–glomerular basement membrane disease antigen 2025 ·Kidney International ·Peter J. Eggenhuizen, Boaz H. Ng, Cecilia Lo, Janet Chang, Sarah L. Snelgrove, (unknown), Chanjuan Shen, Steven Lim, (unknown), Poh‐Yi Gan, Joshua D. Ooi	2
3	Clinical features and prognosis of ANCA-associated vasculitis patients who were double-seropositive for myeloperoxidase-ANCA and proteinase 3-ANCA 2024 ·Clinical and Experimental Medicine ·(unknown), Chanjuan Shen, Ting Meng, Wei Lin, (unknown), Rong Tang, (unknown), Joshua D. Ooi, Peter J. Eggenhuizen, Jinbiao Chen, Yaou Zhou, Hui Luo, (unknown), Ning Liu, Ping Xiao, Xiangcheng Xiao, Yong Zhong	3
4	Hydroxychloroquine as an add-on therapy for the induction therapy of MPO-AAV: a retrospective observational cohort study 2024 ·Clinical Kidney Journal ·(unknown), Ting Meng, Wei Lin, (unknown), (unknown), (unknown), Joshua D. Ooi, Peter J. Eggenhuizen, Jinbiao Chen, Yaou Zhou, Hui Luo, (unknown), Ning Liu, Ping Xiao, Xiangcheng Xiao, Yong Zhong	0
5	Development of a radiomics nomogram to predict the treatment resistance of Chinese MPO-AAV patients with lung involvement: a two-center study 2023 ·Frontiers in Immunology ·(unknown), Ting Meng, (unknown), Joshua D. Ooi, Peter J. Eggenhuizen, Wenguang Liu, Fang Li, Xueqin Wu, Jian Sun, (unknown), Yaou Zhou, Hui Luo, Xiangcheng Xiao, Yigang Pei, Wenzheng Li, Yong Zhong	1
6	Single-cell transcriptomics uncover hub genes and cell–cell crosstalk in patients with hypertensive nephropathy 2023 ·International Immunopharmacology ·Rong Tang, Wei Lin, Chanjuan Shen, (unknown), (unknown), Ting Meng, (unknown), Peter J. Eggenhuizen, Joshua D. Ooi, Peng Jin, Xiang Ding, Xiangcheng Xiao, Yong Zhong	6
7	Sex disparities in clinicopathological features and outcomes of patients with myeloperoxidase-ANCA-associated vasculitis: a retrospective study of 366 cases in a single Chinese center 2023 ·Clinical and Experimental Medicine ·Ting Meng, (unknown), Chanjuan Shen, Joshua D. Ooi, Peter J. Eggenhuizen, Yaou Zhou, Hui Luo, Jinbiao Chen, Wei Lin, (unknown), (unknown), Rong Tang, Xiang Ao, Weisheng Peng, Zhou Xiao, Ping Xiao, Xiangcheng Xiao, Yong Zhong	1
8	High levels of platelet-to-lymphocyte ratio may predict reduced risk of end stage of renal disease in Chinese patients with MPO-ANCA associated vasculitis 2022 ·PubMed Central ·Li Huang, Chanjuan Shen, Yong Zhong, Joshua D. Ooi, Peter J. Eggenhuizen, Yaou Zhou, Jinbiao Chen, Ting Wu, Ting Meng, Zhou Xiao, Wei Lin, Rong Tang, Xiang Ao, Xiangcheng Xiao, (unknown), Ping Xiao	1
9	Clinical features and prognosis of MPO-ANCA and anti-GBM double-seropositive patients 2022 ·Frontiers in Immunology ·(unknown), Chanjuan Shen, Ting Meng, Joshua D. Ooi, Peter J. Eggenhuizen, Yaou Zhou, Hui Luo, Jinbiao Chen, Wei Lin, (unknown), (unknown), (unknown), Ning Liu, Xiangcheng Xiao, Rong Tang, Yong Zhong	9
10	The effect of discontinuation of maintenance therapy in Chinese patients with MPO-ANCA associated vasculitis who were in long-term stable remission 2022 ·Clinical and Experimental Medicine ·(unknown), Ting Meng, Chanjuan Shen, Joshua D. Ooi, Peter J. Eggenhuizen, Yaou Zhou, Hui Luo, Jinbiao Chen, Wei Lin, Rong Tang, Xiang Ao, Weisheng Peng, Zhou Xiao, (unknown), Xia Li, Qiaoling Zhou, Ping Xiao, Yong Zhong, Xiangcheng Xiao	1
11	Patient Survival Between Hemodialysis and Peritoneal Dialysis Among End-Stage Renal Disease Patients Secondary to Myeloperoxidase-ANCA-Associated Vasculitis 2022 ·Frontiers in Medicine ·Xueqin Wu, Yong Zhong, Ting Meng, Joshua D. Ooi, Peter J. Eggenhuizen, Rong Tang, (unknown), Xiangcheng Xiao, Jian Sun, Xiang Ao, Hao Zhang	4
12	BCG Vaccine Derived Peptides Induce SARS-CoV-2 T Cell Cross-Reactivity 2021 ·Frontiers in Immunology ·Peter J. Eggenhuizen, Boaz H. Ng, Janet Chang, (unknown), (unknown), (unknown), Poh‐Yi Gan, Stephen R. Holdsworth, Joshua D. Ooi	29
13	Glomerular Immune Deposition in MPO-ANCA Associated Glomerulonephritis Is Associated With Poor Renal Survival 2021 ·Frontiers in Immunology ·Wei Lin, Chanjuan Shen, Yong Zhong, Joshua D. Ooi, Peter J. Eggenhuizen, (unknown), Hui Luo, Jing Huang, (unknown), Ting Wu, Ting Meng, Zhou Xiao, Xiang Ao, Weisheng Peng, Rong Tang, Hongling Yin, Xiangcheng Xiao, Qiaoling Zhou, Ping Xiao	29
14	A Partial Picture of the Single-Cell Transcriptomics of Human IgA Nephropathy 2021 ·Frontiers in Immunology ·Rong Tang, Ting Meng, Wei Lin, Chanjuan Shen, Joshua D. Ooi, Peter J. Eggenhuizen, Peng Jin, Xiang Ding, Jinbiao Chen, (unknown), Zhou Xiao, Xiang Ao, Weisheng Peng, Qiaoling Zhou, Ping Xiao, Yong Zhong, Xiangcheng Xiao	58
15	Single-Cell Profiling Reveals Transcriptional Signatures and Cell-Cell Crosstalk in Anti-PLA2R Positive Idiopathic Membranous Nephropathy Patients 2021 ·Frontiers in Immunology ·Jie Xu, Chanjuan Shen, Wei Lin, Ting Meng, Joshua D. Ooi, Peter J. Eggenhuizen, Rong Tang, Gong Xiao, Peng Jin, Xiang Ding, (unknown), Weisheng Peng, (unknown), Xiang Ao, Xiangcheng Xiao, Yong Zhong, Qiaoling Zhou	37
16	Clinical features and outcomes of anti-neutrophil cytoplasmic autoantibody-associated vasculitis in Chinese childhood-onset patients 2021 ·Clinical and Experimental Medicine ·Ting Meng, Chanjuan Shen, Rong Tang, Wei Lin, Joshua D. Ooi, Peter J. Eggenhuizen, Yaou Zhou, Jinbiao Chen, Fang He, Zhou Xiao, Xiang Ao, Weisheng Peng, (unknown), Qiaoling Zhou, Ping Xiao, Yong Zhong, Xiangcheng Xiao	3
17	A plasmid-encoded peptide from Staphylococcus aureus induces anti-myeloperoxidase nephritogenic autoimmunity 2019 ·Nature Communications ·Joshua D. Ooi, Jhih‐Hang Jiang, Peter J. Eggenhuizen, (unknown), (unknown), Khai Lee Loh, Kim M. O’Sullivan, Poh‐Yi Gan, Yong Zhong, Kirill Tsyganov, (unknown), Jessica Ryan, Coen A. Stegeman, Lars Fugger, Hugh H. Reid, Jamie Rossjohn, Peter Heeringa, Stephen R. Holdsworth, Anton Y. Peleg, A. Richard Kitching	45
18	CD8+ T Cells Effect Glomerular Injury in Experimental Anti-Myeloperoxidase GN 2016 ·Journal of the American Society of Nephrology ·Janet Chang, Peter J. Eggenhuizen, Kim M. O’Sullivan, Maliha A. Alikhan, Stephen R. Holdsworth, Joshua D. Ooi, A. Richard Kitching	48
19	FMS-Like Tyrosine Kinase 3 Ligand Treatment Does Not Ameliorate Experimental Rapidly Progressive Glomerulonephritis 2015 ·PLoS ONE ·Joanna R. Ghali, Kim M. O’Sullivan, Peter J. Eggenhuizen, Stephen R. Holdsworth, A. Richard Kitching	1
20	The nebulin SH3 domain is dispensable for normal skeletal muscle structure but is required for effective active load bearing in mouse 2013 ·Journal of Cell Science ·Daniel L. Yamamoto, (unknown), (unknown), David S. Gokhin, Alessandra Castaldi, Gérald Coulis, (unknown), (unknown), Peter J. Eggenhuizen, Paolo Kunderfranco, Serena Camerini, Kazunori Takano, Takeshi Endo, Marco Crescenzi, Pradeep K. Luther, Richard L. Lieber, Ju Chen, Marie‐Louise Bang	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact